Erbitux renews RSA for the first time
Erbitux, a metastatic rectal and colon cancer therapy, successfully renewed the RSA agreement. This is the first case which renewed the agreement through a renegotiation.
According to the National Health Insurance Service(NHIS) on the 14th, Merck and the NHIS have concluded the RSA revaluation a...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.